EA201492262A1 - Конструкция пептидного каркаса - Google Patents

Конструкция пептидного каркаса

Info

Publication number
EA201492262A1
EA201492262A1 EA201492262A EA201492262A EA201492262A1 EA 201492262 A1 EA201492262 A1 EA 201492262A1 EA 201492262 A EA201492262 A EA 201492262A EA 201492262 A EA201492262 A EA 201492262A EA 201492262 A1 EA201492262 A1 EA 201492262A1
Authority
EA
Eurasian Patent Office
Prior art keywords
construction
methods
relates
peptide frame
peptide
Prior art date
Application number
EA201492262A
Other languages
English (en)
Inventor
Биргер Серенсен
Матс Эквист
Арнт Ове Ховден
Мая Соммерфельт Гренвольд
Original Assignee
Бионор Иммуно Ас
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бионор Иммуно Ас filed Critical Бионор Иммуно Ас
Publication of EA201492262A1 publication Critical patent/EA201492262A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/04—Varicella-zoster virus
    • G01N2333/045—Cytomegalovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)

Abstract

Настоящее изобретение относится к новым пептидам и способам лечения, диагностики и прогнозирования вирусных инфекций, включая инфекции HCV, ВИЧ, HPV, CMV и вирусом гриппа. Кроме того, изобретение относится к способам идентификации и предоставления пептидов, пригодных для лечения и диагностики.
EA201492262A 2012-06-06 2013-06-06 Конструкция пептидного каркаса EA201492262A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656256P 2012-06-06 2012-06-06
PCT/EP2013/061751 WO2013182661A1 (en) 2012-06-06 2013-06-06 Peptides derived from viral proteins for use as immunogens and dosage reactants

Publications (1)

Publication Number Publication Date
EA201492262A1 true EA201492262A1 (ru) 2015-08-31

Family

ID=48577073

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492262A EA201492262A1 (ru) 2012-06-06 2013-06-06 Конструкция пептидного каркаса

Country Status (15)

Country Link
US (1) US10501499B2 (ru)
EP (1) EP2859011B1 (ru)
JP (1) JP6310909B2 (ru)
KR (1) KR20150018870A (ru)
CN (1) CN104619718A (ru)
AU (1) AU2013273482A1 (ru)
BR (1) BR112014030466A2 (ru)
CA (1) CA2874923C (ru)
EA (1) EA201492262A1 (ru)
HK (1) HK1207871A1 (ru)
IL (1) IL235891A0 (ru)
IN (1) IN2014KN02769A (ru)
MX (1) MX2014014683A (ru)
NZ (1) NZ702146A (ru)
WO (1) WO2013182661A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121291A2 (en) * 2013-02-04 2014-08-07 University Of Notre Dame Du Lac Nanoparticle drug delivery systems
MA40415A (fr) 2014-09-03 2016-03-10 Immunogen Inc Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3552623A1 (en) * 2016-06-20 2019-10-16 ISA Pharmaceuticals B.V Formulation of a peptide vaccine
BR112019013724A2 (pt) * 2017-01-03 2020-04-14 Emergex Vaccines Holding Ltd composições de vacina influenza universal
CN110548136A (zh) * 2018-05-30 2019-12-10 王美亮 汉坦病毒长肽疫苗
JP7395200B2 (ja) * 2019-03-25 2023-12-11 イミュンワーク インク． 金属結合モチーフを有する複合ポリペプチド及びそれを備える分子構築物
KR102393872B1 (ko) * 2019-08-28 2022-05-04 엠브릭스 주식회사 바이러스 외피를 손상시키는 m2 단백질 유래 항바이러스 펩타이드 및 그의 용도
US20230109142A1 (en) * 2020-02-14 2023-04-06 Immunor As Corona virus vaccine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0596032B2 (en) 1991-07-25 2004-04-07 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
MY111880A (en) 1992-03-27 2001-02-28 Smithkline Beecham Biologicals S A Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a
ES2334181T3 (es) 1992-05-23 2010-03-05 Glaxosmithkline Biologicals S.A. Vacunas combinadas que comprenden antigeno de superficie de la hepatitis b y otros antigenos.
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
ES2197170T3 (es) 1993-11-04 2004-01-01 Innogenetics N.V. Epitopos de celulas t humanas inmunologicamente dominantes del virus de la hepatitis c.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU697171B2 (en) 1994-04-08 1998-10-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE296313T1 (de) 1996-03-21 2005-06-15 Epimmune Inc Hla-a2.1 bindende peptide und deren verwendung
DK0935662T3 (da) 1996-05-24 2006-03-06 Chiron Corp Fusionsprotein med multiple epitoper
US6566330B1 (en) 1996-10-22 2003-05-20 Medical University Of South Carolina Foundation Research Development Positively charged non-natural amino acids, methods of making and using thereof in peptides
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
EA003634B1 (ru) 1998-10-05 2003-08-28 Фармэкса А/С Новые способы терапевтической вакцинации
NO311807B1 (no) * 1999-03-04 2002-01-28 Bionor Immuno As HIV-peptider, antigener, vaksinepreparater, immunoassay- testsett og en metode for påvisning av antistoffer fremkalt av HIV
CA2377525A1 (en) 1999-07-19 2001-03-29 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US20020076415A1 (en) 1999-12-14 2002-06-20 Jing-Hsiung Ou Hepatitis C virus gene products
GB0005703D0 (en) 2000-03-09 2000-05-03 Alpharma As Compounds
WO2002020035A1 (en) 2000-09-01 2002-03-14 Epimmune Inc. Hla binding peptides and their uses
NO314587B1 (no) 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
NO314588B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV-peptider, antigener, vaksinesammensetning, immunoassay- testsett og en fremgangsmåte for å påvise antistoffer indusert av HIV
EP1195381A1 (de) 2000-09-28 2002-04-10 Immusystems GmbH CD4+ T-Lymphozyten spezifische Hepatitis C Virus-Epitope
GB0026094D0 (en) 2000-10-25 2000-12-13 Imp College Innovations Ltd Methods
US7702465B2 (en) 2002-06-10 2010-04-20 Algonomics N.V. Method, computing routine, device for predicting properties of MHC/peptide complexes, and data and peptides produced therefrom
CA2494192C (en) * 2002-08-12 2013-01-22 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and b-cell epitopes
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
EP1652858A1 (en) 2004-10-28 2006-05-03 Innogenetics N.V. Peptides for inducing a CTL and/or HTL response to hepatitis C virus
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
US8252893B2 (en) * 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
WO2008107400A1 (en) 2007-03-02 2008-09-12 Genimmune N.V. Hcv polyepitope construct and uses thereof
EA022788B1 (ru) 2009-07-03 2016-03-31 Бионор Иммуно Ас Новые терапевтические и диагностические средства
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
MX346475B (es) 2011-01-06 2017-03-22 Bionor Immuno As Peptidos inmunogenicos monomericos y multimericos.
US8618303B2 (en) * 2011-01-07 2013-12-31 Hoffmann-La Roche Inc. Pyrrolidine derivatives

Also Published As

Publication number Publication date
US20150152140A1 (en) 2015-06-04
CA2874923A1 (en) 2013-12-12
CN104619718A (zh) 2015-05-13
EP2859011A1 (en) 2015-04-15
IL235891A0 (en) 2015-01-29
JP2015521206A (ja) 2015-07-27
HK1207871A1 (en) 2016-02-12
IN2014KN02769A (ru) 2015-05-08
KR20150018870A (ko) 2015-02-24
JP6310909B2 (ja) 2018-04-11
US10501499B2 (en) 2019-12-10
NZ702146A (en) 2016-11-25
CA2874923C (en) 2021-08-31
BR112014030466A2 (pt) 2017-09-12
AU2013273482A1 (en) 2014-12-11
MX2014014683A (es) 2015-02-24
EP2859011B1 (en) 2019-12-11
WO2013182661A1 (en) 2013-12-12

Similar Documents

Publication Publication Date Title
EA201390806A1 (ru) Конструкция пептидного каркаса
EA201492262A1 (ru) Конструкция пептидного каркаса
EA201790630A1 (ru) Способы получения рибозидов
EA201391011A1 (ru) Мономерные и мультимерные иммуногенные пептиды
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
EA201490588A1 (ru) Способы лечения вируса гепатита с
EA201491423A1 (ru) Соединения имидазопирролидинонов
EA201391170A1 (ru) Терапевтическое средство на основе дрожжей для лечения хронического гепатита b
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
BR112015022790A8 (pt) molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
ECSP11010823A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
MX2019007921A (es) Nuevos agentes de union a ha.
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
MX352604B (es) Composiciones inmunogenicas de la glucoproteina g de los virus hendra y nipah.
EA201490288A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирусы гриппа a филогенетической группы 1 и филогенетической группы 2 и вирусы гриппа b
EA201400274A1 (ru) Связующая молекула, обладающая нейтрализующей активностью в отношении вируса гриппа а, полученная из в-клеток человека
TR201905619T4 (tr) Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201390856A1 (ru) Инактивация вирусов с применением улучшенного способа растворитель-детергент
EA201600476A1 (ru) Вариант вируса ppcc, клон кднк вируса ppcc европейского типа и их применение
FR2969926B1 (fr) Arabinogalactanes, apiogalacturonanes et heteroglycanes sulfates pour le traitement des maladies causees par les virus influenza
EA201500643A1 (ru) Парвовирус свиней 5а, способы применения и вакцина
CL2016000300A1 (es) Métodos terapéuticos
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection